No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Investors Are Less Pessimistic Than Expected
Research Reports digging for gold丨Huayuan Securities: Maintain Shenzhen Salubris Pharmaceuticals 'Buy' rating, the downstream chronic disease market has vast potential.
Huayuan Securities Research Reports pointed out that Shenzhen Salubris Pharmaceuticals (002294.SZ) is one of the leaders in China's chronic disease sector, with many years of investment in the cardiovascular field, and has maintained high R&D spending for several years (in 2023, R&D expenditures exceeded 1 billion, accounting for 31% of revenue). After the painful period of centralized procurement from 2018 to 2020, the Innovative Drugs Sector has started to scale up, and major products for hypertension and heart failure are expected to soon deliver results, with development likely entering a new stage driven by innovation. From single ingredients to compound medicines, from initial treatment to comprehensive management, the company's hypertension product cluster is set to gradually upgrade, with competitiveness continuously strengthening. Companies selected include Haisco Pharmaceutical Group, Jiangsu Hengrui Pharmaceuticals, and Betta Pharmaceuticals.
Is The Market Rewarding Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Chinese Drug Regulator Accepts Salubris Pharmaceuticals' Application to Trial Hypertension Drug
Huayoung Asia Vets (301502.SZ): The main clients of the injection pen Business include well-known biopharmaceutical companies such as Jinsai Pharmaceuticals, Haosen Pharmaceuticals, and Shenzhen Salubris Pharmaceuticals.
On February 13, Gelonghui reported that Huayang Intelligent (301502.SZ) stated during an investor relations activity that the company's precision drug delivery devices are primarily divided into electronic and Machinery injection pens. The electronic injection pen is the company's core product, which also includes a series of Machinery injection pen products. The company is one of the early starters in domestic injection pen production with a relatively complete product line, and its main clients include well-known biopharmaceutical companies such as Jin Sai Pharmaceutical, Hao Sen Pharmaceutical, and Shenzhen Salubris Pharmaceuticals. The future market space for injections is vast. There is great growth potential for diabetes medications, weight loss drugs, etc., and the domestic penetration rate for growth hormones and osteoporosis medications is still very low, along with Other medications such as follicle-stimulating hormones and monoclonal antibodies.